Company profilePharmaceutical#123 of 1,318 in Pakistan✓ No DRAP alerts

MS SIZA INTERNATIONAL PVT LTD.

Pharmaceutical company · 136 brands · 134 molecules

Ranked #11 of 39 companies in Calcium Channel Blockers

136 registered products 41 pharmaceutical brands 134 distinct molecules 0 DRAP alerts

Company overview

136
registered products
41
pharmaceutical brands
134
distinct molecules
4
therapeutic classes
0
DRAP alerts

MS SIZA INTERNATIONAL PVT LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 136 product registrations across 134 distinct molecules. It is the 123rd largest registrant in Pakistan by product count, and ranks 11th of 39 in Calcium Channel Blockers. Its portfolio is concentrated in Calcium Channel Blockers and Lipid Modifying Agents. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by MS

19 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

19
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202619

Top molecules by brand count

Cephalexin5 brands
Cefixime3 brands
Amlodipine3 brands
Linezolid3 brands
Amikacin3 brands
Simvastatin3 brands

Therapeutic classes

Calcium Channel Blockers · 1Lipid Modifying Agents · 1Quinolone Antibacterials · 1Antiemetics & Antinauseants · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official149 products · Rs 3.53 – Rs 4,962.38
Median across source: Rs 323.95

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD. holds 150 molecules not in this portfolio
AlbuterolAmikacinAminophyllineAmlodipineAmlodipine BaseAmmonium Chloride
MEDIATE PHARMACEUTICALS (PVT) LTD holds 112 molecules not in this portfolio
AcyclovirAlendronateAmlodipineAmoxicillinAmpicillinAmpicillin Base
SEARLE PAKISTAN (PVT.) LTD. holds 233 molecules not in this portfolio
AcetazolamideAdalimumabAlprazolamAmilorideAminophyllineAmitriptyline

Get the full profile for MS

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.